The Association of Erythropoietin and Age-Related Macular Degeneration in Hemodialysis Patients: A Nationwide Population-Based Cohort Study

This population-based retrospective cohort study investigated the effectiveness of erythropoietin (EPO) treatment in reducing the risk of age-related macular degeneration (AMD) in hemodialysis patients, using the National Health Insurance Research Data of Taiwan. From the database, we identified 147,318 end-stage renal disease (ESRD) patients on hemodialysis who had been diagnosed in 2000–2014 to establish the propensity-score-matched EPO user cohort and non-EPO user cohort with equal sample size of 15,992. By the end of 2016, the cumulative incidence of AMD in EPO users was about 3.29% lower than that in non-EPO users (Kaplan–Meier survival p p p < 0.0001). Our findings suggest that EPO treatment for hemodialysis patients could reduce AMD risk in a dose–response relationship

Variations in RNFL thickness of different segments with axial length.

<p>Variations in RNFL thickness of different segments with axial length.</p

The inverse correlation between RNFL thickness and axial length.

<p>The inverse correlation between RNFL thickness and axial length.</p

Differences in RNFL thickness of the different segments among the three age groups.

<p>Differences in RNFL thickness of the different segments among the three age groups.</p

The number of eyes and participants that met the criteria for inclusion or exclusion.

<p>The number of eyes and participants that met the criteria for inclusion or exclusion.</p

Characteristics of the 82 study participants and mean RNFL thicknesses of different segments.

<p>Characteristics of the 82 study participants and mean RNFL thicknesses of different segments.</p